[go: up one dir, main page]

PE20070490A1 - Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 - Google Patents

Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1

Info

Publication number
PE20070490A1
PE20070490A1 PE2006001183A PE2006001183A PE20070490A1 PE 20070490 A1 PE20070490 A1 PE 20070490A1 PE 2006001183 A PE2006001183 A PE 2006001183A PE 2006001183 A PE2006001183 A PE 2006001183A PE 20070490 A1 PE20070490 A1 PE 20070490A1
Authority
PE
Peru
Prior art keywords
ona
muscarine
benzymidazole
piperidine
receptor agonists
Prior art date
Application number
PE2006001183A
Other languages
English (en)
Inventor
Brian Budzik
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul William Smith
Graham Walker
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20070490A1 publication Critical patent/PE20070490A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R4 ES FLUOR; R5 ES H, HALOGENO, CN, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON F O ALCOXI(C1-C6), ENTRE OTROS; R6 ES HALOGENO, CN, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON F O CICLOALQUILO(C3-C6), ENTRE OTROS; Q ES H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: 4-FLUORO-6-METIL-1-[1-(TETRAHIDRO-2H-PIRAN-4-IL)-4-PIPERIDINIL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, 6-CLORO-4-FLUORO-1-[1-(TETRAHIDRO-2H-PIRAN-4-IL)-4-PIPERIDINIL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, 4-FLUORO-6-METOXI-1-[1-(TETRAHIDRO-2H-PIRAN-4-IL)-4-PIPERIDINIL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR MUSCARINICO M1 SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS PSICOTICOS Y ALTERACIONES COGNITIVAS TAL COMO TRASTORNOS DE LA ATENCION, ORIENTACION, APRENDIZAJE, MEMORIA
PE2006001183A 2005-09-30 2006-09-28 Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 PE20070490A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds

Publications (1)

Publication Number Publication Date
PE20070490A1 true PE20070490A1 (es) 2007-05-30

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001183A PE20070490A1 (es) 2005-09-30 2006-09-28 Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1

Country Status (24)

Country Link
US (2) US8283364B2 (es)
EP (1) EP1943230B1 (es)
JP (1) JP5209480B2 (es)
KR (2) KR101374458B1 (es)
CN (1) CN101321736B (es)
AR (1) AR056103A1 (es)
AT (1) ATE492537T1 (es)
AU (1) AU2006296369B2 (es)
BR (1) BRPI0616609A2 (es)
CA (1) CA2624504C (es)
CR (1) CR9904A (es)
DE (1) DE602006019119D1 (es)
EA (1) EA016286B1 (es)
IL (1) IL190219A (es)
JO (1) JO2634B1 (es)
MA (1) MA29849B1 (es)
MY (1) MY148504A (es)
NO (1) NO20081945L (es)
NZ (1) NZ566508A (es)
PE (1) PE20070490A1 (es)
TW (1) TWI389905B (es)
UA (1) UA101299C2 (es)
WO (1) WO2007036715A2 (es)
ZA (1) ZA200802167B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
WO2016073294A1 (en) * 2014-11-03 2016-05-12 William Beaumont Hospital Method for treating underactive bladder syndrome
UY36654A (es) 2015-04-29 2016-10-31 Janssen Pharmaceutica Nv Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
KR20170141769A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) * 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) * 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANTAGONISTS
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
EP1221443B1 (en) 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
WO2001057019A1 (en) * 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
SI1975164T1 (sl) * 2001-04-18 2010-05-31 Euro Celtique Sa Oktahidrobenzimidazolonske spojine kot analgetiki
CA2444595A1 (en) 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
KR100809569B1 (ko) * 2001-10-02 2008-03-04 아카디아 파마슈티칼스 인코포레이티드 무스카린 제제로서 벤즈이미다졸리디논 유도체
CA2465328C (en) * 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
AU2003245565B2 (en) 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
US7645771B2 (en) 2002-12-13 2010-01-12 Smithkline Beecham Corp. CCR5 antagonists as therapeutic agents
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
CN1823062A (zh) * 2003-07-23 2006-08-23 惠氏公司 作为5－羟色胺－6配体的磺酰基二氢苯并咪唑酮化合物
DK1664036T3 (da) * 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
MX2007005290A (es) * 2004-11-02 2007-07-09 Pfizer Derivados de sulfonilbencimidazol.
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8288412B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8288413B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
RU2422116C2 (ru) 2006-09-08 2011-06-27 Дзе Жиллетт Компани Устройство для гигиены ротовой полости, зубная щетка (варианты) и способ обеспечения множества чистящих операций единственной зубной щеткой
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
MY148504A (en) 2013-04-30
CN101321736A (zh) 2008-12-10
CA2624504C (en) 2014-07-08
JP5209480B2 (ja) 2013-06-12
AR056103A1 (es) 2007-09-19
TWI389905B (zh) 2013-03-21
CA2624504A1 (en) 2007-04-05
BRPI0616609A2 (pt) 2011-06-28
WO2007036715A3 (en) 2007-05-18
WO2007036715A2 (en) 2007-04-05
US8481566B2 (en) 2013-07-09
KR20130091791A (ko) 2013-08-19
US20080255195A1 (en) 2008-10-16
KR20080049090A (ko) 2008-06-03
KR101374458B1 (ko) 2014-03-17
NO20081945L (no) 2008-06-04
EP1943230A2 (en) 2008-07-16
DE602006019119D1 (de) 2011-02-03
AU2006296369A1 (en) 2007-04-05
US20080058378A1 (en) 2008-03-06
JP2009512635A (ja) 2009-03-26
UA101299C2 (uk) 2013-03-25
JO2634B1 (en) 2012-06-17
TW200806657A (en) 2008-02-01
EA200801001A1 (ru) 2008-08-29
CN101321736B (zh) 2012-04-04
CR9904A (es) 2008-07-29
IL190219A (en) 2012-10-31
US8283364B2 (en) 2012-10-09
IL190219A0 (en) 2008-11-03
AU2006296369B2 (en) 2012-12-20
NZ566508A (en) 2011-07-29
ATE492537T1 (de) 2011-01-15
MA29849B1 (fr) 2008-10-03
EP1943230B1 (en) 2010-12-22
ZA200802167B (en) 2009-08-26
EA016286B1 (ru) 2012-03-30

Similar Documents

Publication Publication Date Title
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20080007A1 (es) Compuestos derivados de bencimidazolona que tienen actividad en el receptor m1
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20070586A1 (es) Compuestos de (4-piperidinil)-1,3-dihidro-2h-bencimidazol-2-ona sustituidos como agonistas del receptor muscarinico m1
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20160839A1 (es) Derivados de 4-azaindol
PE20090057A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20110894A1 (es) Derivados de pirimidin indol para el tratamiento de cancer
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed